This association between high IL-1β expression and adverse clinical outcomes is further supported by pooled survival data from selected studies, which collectively demonstrate a significant increase in recurrence and mortality risk in IL-1β-high breast cancer cases (Figure 4). The gene discussed is IL1B; the disease is breast cancer.